Secukinumab (Cosentyx)

What is secukinumab?

Secukinumab (Cosentyx) is an injectable biologic medication used in dermatology for moderate-to-severe plaque psoriasis and psoriatic arthritis. It is part of the IL-17 biologic class and may also be relevant in dermatology because it is approved for hidradenitis suppurativa.

How does secukinumab work?

Secukinumab targets interleukin-17A (IL-17A), an inflammatory signal involved in psoriasis. By reducing activity in this pathway, secukinumab can help improve plaque thickness, scaling, and skin inflammation.

This mechanism places it in the same general pathway as some other high-level psoriasis biologics, although individual medications can still differ in practical use and dosing.

What are possible side effects of secukinumab?

Possible side effects can include:

  • Upper respiratory symptoms

  • Diarrhea in some patients

  • Injection site reactions

  • Yeast infections and possible inflammatory bowel disease concerns in some patients

As with other biologic medications, infection screening, vaccination review, and overall treatment risks should be discussed with the prescribing clinician. A history of recurrent yeast infections or inflammatory bowel disease may affect treatment discussions.

How is secukinumab used?

Secukinumab is given by injection on a schedule directed by your provider. Some patients may be able to self-inject after training. The medication is stored in the refrigerator.

In clinical practice, secukinumab is one of the established IL-17 biologics often compared with other advanced psoriasis treatments. Treatment choice may also be influenced by hidradenitis symptoms, joint disease, prior biologic experience, and payer requirements.

THIS CONTENT IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES AND MAY NOT BE COMPREHENSIVE. IT DOES NOT CONSTITUTE MEDICAL ADVICE. PLEASE REFER TO OUR TERMS OF USE FOR FURTHER DETAILS. ALWAYS CONSULT WITH YOUR HEALTHCARE PROVIDER BEFORE MAKING ANY MEDICAL DECISIONS.